top of page

Maxwellia CEO Anna Maxwell Nominated for 2025 Northern Power Women Awards

Maxwellia is proud to announce that our CEO, Anna Maxwell, has been shortlisted for the 2025 Northern Power Women Awards in the ‘Inclusive Innovation - Tech for Good’ category. This nomination reflects Anna’s unwavering commitment to revolutionising medicine access, particularly for historically underserved demographics.

At Maxwellia, Anna is pioneering a unique approach to healthcare through ‘switching’ – converting prescription-only medicines into over the counter (OTC) products. Her mission is to empower people to manage their health more independently, eliminating barriers such as long waiting times for GP appointments. Our game changing products – including LoviOne®, our OTC emergency contraceptive pill, and Evana®, the first OTC solution for heavy periods – are already making significant strides in giving women greater control over their health.

Anna’s leadership and dedication are reflected in her long-standing career as a pharmacist and entrepreneur. She has been a champion for inclusive innovation, ensuring that the solutions we develop meet the real-world needs of those who are often overlooked by the healthcare system. Products like LoviOne® and Evana® are designed not just to address health issues, but also to make medicines more accessible, affordable, and inclusive for all.

Northern Power Anna Image.png

This nomination underscores her commitment to creating a more inclusive healthcare landscape – one that addresses the gender health gap and offers practical, OTC solutions for reproductive and menstrual health. It also highlights the importance of making innovative medicines solutions available to everyone.

 

As we continue to expand our efforts, we invite partners and investors to join Anna on this journey. Maxwellia is currently raising £2 million to help scale our operations and bring more life-changing medicines to market. We are looking for 100 investors to be part of this exciting growth phase. For more information on this opportunity, visit our 2024 Investor Fund Raise page.

Together, we are creating a brighter future for healthcare—one that is inclusive, accessible, and empowering.

Lovima® 75mcg film-coated tablets. Desogestrel. Oral contraception.  LoviOne® 1.5mg tablet. Levonorgestrel. Emergency contraception. Always read the label. Evana® Heavy Period Relief 500 mg tablets. Tranexamic acid. Ultravana® Period Pain Relief 250 mg Gastro-resistant tablets. Naproxen. Always read the label.

bottom of page